The iPSC-derived Human Forebrain Neural Progenitor Cell Injection hNPC01 of Hopstem has Received CDE's Clinical Implication Approval
The launch meeting of the clinical research project of Hopstem hNPC01 universal cell therapy product for the treatment of stroke sequelae was successfully held.
Good news! Hopstem has been awarded as one of the "Top 10 Organoid Enterprises with the Most Investment Value"!
Hopstem has honored to list on the “2023 Top 100 Future Healthcare List”
Join the leader of iPSC Cell Therapy！